Advertisement

Topics

BRIEF—EMA accepts Mylan and Biocon's proposed biosimilars trastuzumab and pegfilgrastim

10:20 EST 1 Dec 2017 | thePharmaLetter

The European Medicines Agency has accepted for review Mylan's Marketing Authorization Applications (MAA)…

Original Article: BRIEF—EMA accepts Mylan and Biocon's proposed biosimilars trastuzumab and pegfilgrastim

NEXT ARTICLE

More From BioPortfolio on "BRIEF—EMA accepts Mylan and Biocon's proposed biosimilars trastuzumab and pegfilgrastim"

Advertisement
Quick Search
Advertisement
Advertisement